Who
Samraat S. Raha
President and CEO
Company insider
Files Form 4 as: President and CEO, Myriad Genetics; Sr. Vice President, Agilent Technologies.
In numbers
- Trades disclosed
- 72
- Buys
- 1
- Sells
- 1
- Bought
- $400K
- Sold
- $128K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 May 2018
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | $14K3,542 at $3.94 | filing |
| 11 Jun 2026filed 12 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | $14K3,542 at $3.94 | filing |
| 14 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $50K10,816 at $4.66 | filing |
| 14 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $50K10,816 at $4.66 | filing |
| 13 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $169K36,304 at $4.66 | filing |
| 13 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $169K36,304 at $4.66 | filing |
| 12 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —618,557 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —618,557 at $0.00 | filing |
| 9 Mar 2026filed 9 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Bought | $200K40,000 at $5.00 | filing |
| 9 Mar 2026filed 9 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Bought | $200K40,000 at $5.00 | filing |
| 11 Dec 2025filed 12 Dec 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $216K29,634 at $7.30 | filing |
| 31 May 2025filed 2 Jun 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | $5,3331,498 at $3.56 | filing |
| 30 Apr 2025filed 1 May 2025 | MYGN Myriad Geneticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —141,050 at $0.00 | filing |
| 14 Mar 2025filed 17 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $77K7,649 at $10.07 | filing |
| 13 Mar 2025filed 17 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —216,495 at $0.00 | filing |
| 11 Dec 2024filed 12 Dec 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $429K29,578 at $14.51 | filing |
| 30 Nov 2024filed 2 Dec 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | $15K1,118 at $13.83 | filing |
| 14 Mar 2024filed 18 Mar 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —64,494 at $0.00 | filing |
| 11 Dec 2023filed 11 Dec 2023 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —236,360 at $0.00 | filing |
| 17 Nov 2023filed 20 Nov 2023 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code F | $179K1,578 at $113.15 | filing |
News
Myriad Genetics Reports New MRD Detection Data In Colorectal And Pancreatic CancersMYGN · rttnews.com · 22 Oct 2026Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)MYGN · tickerreport.com · 20 Oct 2026Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing BusinessMYGN · investorideas.com · 20 Oct 2026
0 headlines in the last 90 days name Samraat S. Raha; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.